<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575301</url>
  </required_header>
  <id_info>
    <org_study_id>2011DIRECT01 (GLP)</org_study_id>
    <nct_id>NCT01575301</nct_id>
  </id_info>
  <brief_title>DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists</brief_title>
  <acronym>DIRECTGLP</acronym>
  <official_title>DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect a cohort of patients treated with GLP-1R Agonists and
      to assess phenotypic, genetic and genomic biomarkers of glycaemic response to these agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To develop a cohort of patients treated with GLP-1 R Agonists who are phenotyped at baseline
      and at 6 month follow up to determine clinical, imaging and other biomarker predictors of
      glycaemic response to GLP-1R Agonists. The hypothesis is that one, or a combination, of these
      biomarkers is associated with glycaemic response to GLP-1R Agonists. The primary outcome is
      therefore HbA1c reduction after 6 months of GLP-1R A treatment.

      This is a cohort study of 800 patients being treated with either exenatide or liraglutide for
      6 months, and carried out in 4 UK centres.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 11, 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c between baseline and 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome is the change in HbA1c (absolute difference between the baseline and 6 month measure) in mmol/mol</description>
  </primary_outcome>
  <enrollment type="Actual">411</enrollment>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide, Liraglutide</intervention_name>
    <description>Dosage, frequency and duration not specified by protocol</description>
    <other_name>Byetta</other_name>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type 2 diabetes where a clinical decision has been made to commence a
             GLP-1R agonist

          -  Either:

               1. On any combination of oral hypoglycaemic agents

               2. On Insulin (+/- oral hypoglycaemic agents)

          -  HbA1c ≥7.5% (58mmol/mol) and HbA1c &lt; 12% (108mmol/mol)

          -  White European

          -  Age ≥ 18 and &lt; 80

        Exclusion Criteria:

          -  Type 1 diabetes

          -  HbA1c &lt;7.5% (58 mmol/mol)

          -  HbA1c ≥ 12% (108 mmol/mol)

          -  Pregnancy or lactation

          -  Any other significant medical reason for exclusion as determined by the investigator

          -  Inability to consent

          -  Participating in a CTIMP during the study period and within 30 days prior to study
             start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewan Pearson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Hospitals NHS Trust</name>
      <address>
        <city>Newcastle</city>
        <state>Teeside</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2012</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Ewan Pearson</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>GLP-1R agonist</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

